{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:56:18Z","timestamp":1785452178075,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anakinra is a recombinant interleukin-1 (IL-1) receptor antagonist used in systemic juvenile idiopathic arthritis (sJIA), refractory Kawasaki disease (KD) and cryopyrin-associated autoinflammatory syndrome (CAPS). Anakinra associated hepatotoxicity, while rare, has been described in several cases in daily practice. \u200bIn this case series the authors describe three pediatric patients with this side effect in the setting of severe macrophage activation syndrome (MAS) in KD and sJIA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>The first patient was a 12-year-old boy who presented with fever, maculo-papular exanthema and polyarthralgia. Tonsillitis, distal limb induration and tender cervical lymph nodes were observed. Erythrocyte-sedimentation rate (ESR), C-reactive protein (CRP), ferritin (11,975 ng\/mL), D-dimers (5,98\u00a0mg\/L FEU) and soluble CD25 (3645 pg\/mL) levels were elevated. Exclusion of sepsis \/ toxic shock syndrome warranted introduction of IV methylprednisolone and immunoglobulin (IG IV), with partial response. A MAS secondary to KD was assumed, and anakinra 2\u00a0mg\/kg\/day was introduced. Twenty days later he developed new-onset nausea and severe cyto-cholestasis, normalizing after 2 months of drug discontinuation. Posterior onset of polyarthritis and evanescent lead to a final diagnosis of sJIA. The second patient was a 2-year-old boy with a 10-day history of fevers, generalized rash, hepatosplenomegaly and strawberry tongue. Leucocytosis with neutrophilia and elevated CRP were observed. Initial treatment with IVIG in the setting of incomplete KD was ineffective. Mild anaemia, leukopenia and very high serum ferritin (maximum 26,128 ng\/mL) ensued. Presumptive sJIA associated MAS was treated with IV methylprednisolone and anakinra 2\u00a0mg\/kg\/day, with prompt response. Four weeks later transaminitis was detected, and temporary anakinra suspension led to normalisation of laboratorial values. The third case related to a 4-year-old boy presenting with fever, maculopapular rash and cervical lymphadenopathy. CRP and ESR were elevated, and KD was diagnosed. IVIG and methylprednisolone were initiated with clinical worsening, warranting for anakinra introduction at 2\u00a0mg\/kg\/day. After three weeks, liver enzymes progressively elevated, resolving on 2 weeks of anakinra discontinuation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>To the best of our knowledge, this is the first case series describing anakinra associated hepatotoxicity in pediatric patients with rheumatic diseases other than sJIA, bringing additional insight to therapeutic monitoring in patients undergoing this treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-023-00891-y","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:02:20Z","timestamp":1696615340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anakinra and hepatotoxicity in pediatric rheumatology: a case series"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9742-2677","authenticated-orcid":false,"given":"Frederico Raj\u00e3o","family":"Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Costa","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ganh\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","first-page":"1759720X2095957","DOI":"10.1177\/1759720X20959575","volume":"12","author":"V Maniscalco","year":"2020","unstructured":"Maniscalco V, Abu-Rumeileh S, Mastrolia MV, et al. The off-label use of anakinra in pediatric systemic autoinflammatory diseases. Ther Adv Musculoskelet Dis. 2020;12:1759720X20959575. https:\/\/doi.org\/10.1177\/1759720X20959575.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"891_CR2","unstructured":"Anakinra. LiverTox Clin Res Inf Drug-Induced Liver Inj. April 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548615\/."},{"issue":"1","key":"891_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/PHAR.1677","volume":"36","author":"SA Taylor","year":"2016","unstructured":"Taylor SA, Vittorio JM, Martinez M, et al. Anakinra-Induced Acute Liver failure in an adolescent patient with still\u2019s disease. Pharmacotherapy. 2016;36(1):e1\u2013e4. https:\/\/doi.org\/10.1002\/PHAR.1677.","journal-title":"Pharmacotherapy"},{"issue":"suppl2","key":"891_CR4","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/RHEUMATOLOGY\/KEG326","volume":"42","author":"JM Dayer","year":"2003","unstructured":"Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology. 2003;42(suppl2):ii3\u2013ii10. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEG326.","journal-title":"Rheumatology"},{"key":"891_CR5","doi-asserted-by":"publisher","unstructured":"Green EA, Metz D, Galinsky R, et al. Anakinra Pilot - a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/FIMMU.2022.1022104.","DOI":"10.3389\/FIMMU.2022.1022104"},{"key":"891_CR6","doi-asserted-by":"publisher","unstructured":"Singh HO, Samani D, Nema V, Ghate MV, Gangakhedkar RR. IL-1RN and IL-1 \u03b2 Polymorphism and ARV-Associated Hepatotoxicity. Mediators Inflamm. 2018;2018. https:\/\/doi.org\/10.1155\/2018\/4398150.","DOI":"10.1155\/2018\/4398150"},{"key":"891_CR7","unstructured":"Kineret. Annex I. Summary of Product Characteristics; 2021."},{"issue":"11","key":"891_CR8","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/ART.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Dav\u00ec S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol (Hoboken NJ). 2014;66(11):3160\u20139. https:\/\/doi.org\/10.1002\/ART.38802.","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"issue":"3","key":"891_CR9","doi-asserted-by":"publisher","first-page":"E122","DOI":"10.1111\/J.1440-1754.2011.02213.X","volume":"48","author":"E Hiejima","year":"2012","unstructured":"Hiejima E, Komatsu H, Takeda Y, et al. Acute liver failure in young children with systemic-onset juvenile idiopathic arthritis without macrophage activation syndrome: report of two cases. J Paediatr Child Health. 2012;48(3):E122\u20135. https:\/\/doi.org\/10.1111\/J.1440-1754.2011.02213.X.","journal-title":"J Paediatr Child Health"},{"issue":"1","key":"891_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/S10238-019-00596-1","volume":"20","author":"G Mammadov","year":"2020","unstructured":"Mammadov G, Liu HH, Chen WX, et al. Hepatic dysfunction secondary to Kawasaki disease: characteristics, etiology and predictive role in coronary artery abnormalities. Clin Exp Med. 2020;20(1):21\u201330. https:\/\/doi.org\/10.1007\/S10238-019-00596-1.","journal-title":"Clin Exp Med"},{"issue":"4","key":"891_CR11","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/BLOOD-2004-08-2997","volume":"105","author":"AD Billiau","year":"2005","unstructured":"Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-\u03b3-producing lymphocytes and IL-6- and TNF-\u03b1-producing macrophages. Blood. 2005;105(4):1648\u201351. https:\/\/doi.org\/10.1182\/BLOOD-2004-08-2997.","journal-title":"Blood"},{"key":"891_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1546-0096-7-21","volume":"7","author":"S Canna","year":"2009","unstructured":"Canna S, Frankovich J, Higgins G, et al. Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr Rheumatol Online J. 2009;7:21. https:\/\/doi.org\/10.1186\/1546-0096-7-21.","journal-title":"Pediatr Rheumatol Online J"},{"key":"891_CR13","unstructured":"Phadke O, Prahalad SR-SK. Reversible hepatotoxicity to IL-1\/IL-6 Blockade in Pediatric patients with systemic juvenile idiopathic arthritis and macrophage activation syndrome [abstract]. Arthritis Rheumatol 2020; 72 (suppl 4). https:\/\/acrabstracts.org\/abstract\/reversible-hepatotoxicity-to-il-1-il-6-blockade-in-pediatric-patients-with-systemic-juvenile-idiopathic-arthritis-and-macrophage-activation-syndrome\/."},{"issue":"9","key":"891_CR14","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1093\/RHEUMATOLOGY\/KEAB202","volume":"60","author":"GM Murray","year":"2021","unstructured":"Murray GM, Kheng Ng S, Beasley D, Johansen L, Ramanan AV. Severe hepatotoxicity as a rare side effect of anakinra in a patient with systemic JIA. Rheumatology. 2021;60(9):e307\u20138. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAB202.","journal-title":"Rheumatology"},{"issue":"4","key":"891_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/JRHEUM.210563","volume":"49","author":"G Giancane","year":"2022","unstructured":"Giancane G, Papa R, Vastert S, et al. Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the Pharmachild Registry. J Rheumatol. 2022;49(4):398\u2013407. https:\/\/doi.org\/10.3899\/JRHEUM.210563.","journal-title":"J Rheumatol"},{"issue":"6","key":"891_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/S40272-020-00421-3","volume":"22","author":"G Ferrara","year":"2020","unstructured":"Ferrara G, Giani T, Caparello MC, Farella C, Gamalero L, Cimaz R. Anakinra for Treatment-Resistant Kawasaki Disease: evidence from a literature review. Paediatr Drugs. 2020;22(6):645. https:\/\/doi.org\/10.1007\/S40272-020-00421-3.","journal-title":"Paediatr Drugs"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00891-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00891-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00891-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:30:59Z","timestamp":1700393459000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00891-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00891-y","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the studies were conducted in accordance with the Declaration of Helsinki. The ethics committee of Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o has granted an exemption from requiring ethics approval to this study. All efforts were made to protect the identity of the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}